Lead Sponsor

Genentech, Inc.

Age

18 - 64 years

Sex

ALL

Healthy Volunteers

No

•Adult patients, ≥ 18 to \< 65 years of age
•Rheumatoid Arthritis (RA) of \> 6 months duration at baseline (American College of Rheumatology criteria)
•Willing to receive immunization with pneumococcal polysaccharide and tetanus toxoid adsorbed vaccines
•Previous immunization with pneumococcal polysaccharide must have occurred ≥ 3 years of baseline, with tetanus containing vaccine ≥ 5 years
•Methotrexate therapy for at least 8 weeks prior to baseline at stable dose of 7.5-25 mg/week (oral or parenteral)
•Other disease-modifying antirheumatic drugs (DMARDs) must be withdrawn before baseline
•Oral corticosteroids must be at stable dose of \< 10 mg/day prednisone or equivalent
•Body weight ≤ 150 kg at screening

•Major surgery (including joint surgery) within 12 weeks prior to baseline or planned major surgery within 8 weeks after baseline
•History of or current inflammatory joint disease or rheumatic autoimmune disease other than RA
•Pre-existing central nervous system demyelinating or seizure disorders
•Active current or history of recurrent bacterial, viral fungal, mycobacterial and other infections
•Any major episode of infection requiring hospitalization or treatment with intravenous antibiotics within 4 weeks prior to baseline or oral antibiotics within 2 weeks prior to baseline
•Active tuberculosis requiring treatment within 3 years prior to baseline
•Primary or secondary immunodeficiency (history or currently active)
•Intra-articular or parenteral corticosteroids within 4 weeks prior to baseline
•Previous treatment with RoActemra/Actemra

Related studies

NCT07536529 · Inflammatory Joint Diseases, Rheumatoid Arthritis (RA), and more

NCT06329401 · Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, and more

NCT07048197 · Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)

NCT06647069 · Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA)

NCT07484243 · Rheumatoid Arthritis (RA), Rheumatoid Arthritis-Associated Interstitial Lung Disease, and more

A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)